AstraZeneca Pharma shares slip 4% as investors rush to book profits

Over the past year, shares of the pharma player have gained around 65 percent in trade.

AstraZeneca Pharma shares slipped over four percent in trade on September 25 after hitting a fresh lifetime high in the previous session as investors rushed to book profits.

So far in trade today, over 16 lakh shares exchanged hands in trade on the bourses, multiple times higher compared to the one-month daily traded average of 88,400 shares.

The BSE wrote to the pharma player regarding the sudden spurt in volume. "We wish to inform you that we have no information/announcement including pending announcement which in the Company’s opinion may have a bearing on the price/volume behaviour in the scrip," said the company.

At 12.20 pm, AstraZeneca Pharma shares were quoting Rs 7,540 on the BSE, lower by 4.3 percent compared to the previous session's close.

Follow our live blog to catch all the updates

In the previous session, AstraZeneca Pharma India share price rose 12.5 percent intraday on to hit a 52-week high of Rs 7,595 after the company received permission to import for sale & distribution of Durvalumab solution for Infusion.

Durvalumab (IMFINZI) in combination with chemotherapy as neoadjuvant treatment, followed by IMFINZI as monotherapy after surgery, is indicated for the treatment of patients with resectable (tumours 4 cm and/or node positive) NSCLC and no known epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) rearrangements.

Over the past year, shares of the pharma player have gained around 65 percent in trade, as against a 31 percent rise in the Nifty 50 index.

Disclaimer: The views and investment tips expressed by investment experts on Moneycontrol.com are their own and not those of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.